US FDA Heightens Focus On Cannabis With Hiring Of Norman Birenbaum As Public Health Advisor
Industry reps are glad that Birenbaum, who was the chief cannabis policy advisor to the governors of New York and Rhode Island, was given a prominent role at FDA that could spur regulatory action.
You may also be interested in...
Hemp Roundtable says Cannabis Administration and Opportunity Act’s limit of 0.001% THC per 100 g by dry weight for ingredients derived from cannabis to qualify as hemp “would impose a devastating setback to a thriving industry, and further limit opportunities for already struggling hemp farmers.”
While not asking Science Board for recommendations on allowing lawful use of hemp in non-drug products, agency officials gave clear indication of current position on the question.
FDA’s tolerance of sales of hemp-containing supplements isn’t the assurance industry needs for investing in development of ingredients and products which have been shown to provide various health benefits.